1. Chondrosarcoma of the Chest Wall: A Review of 53 Cases from Two Institutions
- Author
-
Giulia Trovarelli, Florian Pohlig, Andrea Angelini, Carolin Knebel, Ruediger von Eisenhart-Rothe, Andreas F Mavrogenis, Antonio Berizzi, Ulrich Lenze, Joerg Theisen, and Pietro Ruggieri
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Chondrosarcoma ,Alive with disease ,bone tumor ,chest wall ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Tumor stage ,Medicine ,Humans ,In patient ,Child ,Thoracic Wall ,Survival rate ,Sarcoma ,chondrosarcoma ,sternum ,Aged ,Retrospective Studies ,Aged, 80 and over ,Rib cage ,business.industry ,General Medicine ,Middle Aged ,Thoracic Neoplasms ,medicine.disease ,Surgery ,Oncology ,030220 oncology & carcinogenesis ,business ,After treatment - Abstract
BACKGROUND/AIM: Chondrosarcomas (CS) of the chest wall are rare, but present an aggressive biological behavior compared to CS of the extremities. The aims of the present study were to determine factors associated with oncological outcomes as well as complications. PATIENTS AND METHODS: We retrospectively analyzed 53 patients (42 primary, 11 recurrent tumors). In total, 39 central CS, 10 peripheral CS, 3 dedifferentiated CS and 1 mesenchymal CS were included. The ribs were most commonly affected (68%). Overall survival and disease-free survival were estimated with Kaplan-Meier analyses and compared with log-rank test. RESULTS: Mean follow-up was 7 years. Negative margins were achieved in 87% of patients. Thirty patients (57%) remained continuously disease-free (NED), three (5%) NED after treatment of relapse, seven (13%) were alive with disease, twelve (23%) were dead with disease and one of other cause. The 10-year survival rate was 81% and 45% in primary and recurrent tumors, respectively. Survival was significantly affected by tumor stage (p
- Published
- 2020